Pituitary

A single patient, six months past debulking surgery for a GH-secreting macroadenoma, with IGF-1 still elevated and a fasting glucose that is quietly drifting the wrong way. The disagreement is which of three real medical options actually fits a body that surgery has only partly fixed.

A single patient, biochemically controlled for three years on monthly injectable octreotide, now asking about the newly approved oral alternative. The disagreement isn't about whether paltusotine works — it's about whether "already controlled" is a reason to leave well enough alone.

A single patient, three years into normal prolactin on cabergoline, asking to stop. The disagreement isn't about whether withdrawal is ever reasonable — it's about whether a residual sliver still visible on her MRI is the specific fact that should keep her on the drug longer than the guideline's own general timeline suggests.

A single patient, incompletely controlled on cabergoline despite two years of dose escalation, now facing a further increase that would put her cumulative exposure into range where echocardiographic monitoring guidance actually changes. The disagreement is whether to keep pushing the dose or change strategy entirely.

A single patient, an 18mm nonfunctioning pituitary adenoma found incidentally, with normal vision, normal hormones, and no complaints. The disagreement is whether to operate before anything goes wrong, or watch and wait for a reason to.

A single patient, a rare TSH-secreting microadenoma, biochemically eligible for either a somatostatin analog or transsphenoidal surgery, and a strong personal preference for the one guidelines treat as second-line. The disagreement is how much that preference should move a decision usually made on surgical-candidacy grounds alone.

A single patient, biochemically confirmed adult growth hormone deficiency after pituitary surgery, weighing whether to start replacement. The disagreement isn't about the diagnosis — it's about how much weight to put on a benefit the literature itself hasn't fully settled.

A single patient, central hypothyroidism confirmed after pituitary surgery, started on levothyroxine with no reliable TSH feedback to titrate against. The disagreement is where in the normal free T4 range the dose should actually land.

A single patient, confirmed ACTH deficiency after pituitary surgery, started on hydrocortisone with an intact renin-angiotensin system that makes her replacement genuinely different from primary adrenal insufficiency, not just a smaller version of it. The disagreement is how much smaller the dose should actually be.

A single patient, hypogonadotropic hypogonadism confirmed after pituitary surgery, wanting both symptom relief and a chance at fathering a child in the next year. The disagreement is whether the conventional first-line treatment is actually first-line for him at all.

A single patient, longstanding type 2 diabetes on a stable insulin regimen, now three weeks out from pituitary surgery that has left him GH- and cortisol-deficient. The disagreement is how far to cut his insulin before his numbers actually prove he needs it cut.

A single patient, two days out from pituitary stalk manipulation during surgery, now producing four liters of dilute urine a day. The disagreement is whether to start scheduled desmopressin now or dose only as symptoms demand, given what the same injury reliably does one week from now.

A single patient, twelve years into permanent central DI after childhood cancer treatment, on a stable desmopressin dose with a sodium that has crept downward over the past two years. The disagreement is whether tighter dosing or a planned weekly gap in coverage is the safer long-term strategy.

A single patient, hours into a sudden severe headache from a bleeding pituitary macroadenoma, with a real but stable visual field deficit and no reduced consciousness. The disagreement is whether stable is good enough to avoid the operating room tonight.

A single patient, three months into combination checkpoint-inhibitor therapy for melanoma, now hypophysitis-confirmed with new adrenal and thyroid axis failure. The disagreement is how to sequence replacement and whether her cancer treatment needs to pause for any of it.

A single patient, six weeks postpartum, with new headache, mild visual symptoms, and a pituitary mass that could be lymphocytic hypophysitis, IgG4-related disease, or an entirely unrelated nonfunctioning adenoma. The disagreement is whether to treat empirically or push for tissue first.

A single patient, on his third recurrence of a silent corticotroph adenoma despite two surgeries and radiotherapy, with imaging showing renewed growth. The disagreement is whether to try a third surgery first or move to temozolomide now, earlier than its traditional place in the sequence.

A single patient, newly pregnant, on cabergoline for a macroprolactinoma close enough to the optic chiasm that standard discontinuation advice may not apply cleanly to her. The disagreement is whether to follow the usual rule or make an explicit exception.

A single patient, an incidentally found empty sella with two borderline hormone axes, neither clearly failed nor clearly normal. The disagreement is whether borderline results in a structurally abnormal gland should be treated as deficiency now or watched until they resolve into a clearer answer.

A single patient, two years past craniopharyngioma resection, with severe hyperphagia-driven obesity that hasn't responded to any lifestyle intervention. The disagreement is which of two real pharmacologic options — one repurposed, one built specifically for this problem — fits her mechanism better.

A single patient, acromegaly inadequately controlled on first-generation somatostatin analog therapy, with established type 2 diabetes already imperfectly managed. The disagreement is whether switching to a more effective agent is worth its well-documented cost to his glucose control, and what to do about that cost if it isn't avoidable.

A single patient, five days out from suprasellar tumor resection, with hyponatremia and labs that fit both cerebral salt wasting and SIADH almost equally well. The disagreement is which one she actually has, since treating one as if it were the other risks real harm.

A single patient, two years past a postpartum hemorrhage severe enough to require transfusion, now presenting with a hormonal picture consistent with Sheehan syndrome. The disagreement is whether to complete full dynamic testing before treating, or start replacement now and test around it.